Tsung-Hsing Chen1,2, Cheng-Tang Chiu1, Chieh Lee3, Yin-Yi Chu1, Hao-Tsai Cheng1, Jun-Te Hsu4, Ren-Chin Wu5, Ta-Sen Yeh6, Kwang-Huei Lin7,8,9. 1. Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 2. Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan. 3. Department of Industrial Engineering and Management, Yuan Ze University College of Engineering, Chung-Li City, Taiwan. 4. Department of Surgery, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 259 Wen-hwa 1 Road, Taoyuan, Taiwan. 5. Department of Pathology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 6. Department of Surgery, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 259 Wen-hwa 1 Road, Taoyuan, Taiwan. tsy471027@cgmh.org.tw. 7. Graduate Institute of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan, Taiwan. khlin@mail.cgu.edu.tw. 8. Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. khlin@mail.cgu.edu.tw. 9. Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan. khlin@mail.cgu.edu.tw.
Abstract
BACKGROUND: Gastric cancer has a poor outcome and identifying useful biomarkers from peripheral blood or tissue could allow its early detection, or potentially precancerous changes, thus improving the curative rates. MicroRNAs (miRNAs) have been shown to offer great potential in cancer diagnosis and prediction. AIM: Here, we investigated the role of plasma miRNAs in the natural course of gastric cancer, from intestinal metaplasia to early cancer. The findings were used to understand whether patients at a high risk of malignancy could be given appropriate interventions in the early disease process, such as using endoscopic submucosal dissection to treat gastric dysplasia or early gastric cancer. METHODS: Participants were divided into healthy control, intestinal metaplasia (IM), and dysplasia/early cancer (pT1a/b) groups. Microarray was used to select potential markers in tissue. RESULTS: Quantitative real-time polymerase chain reaction data showed circulating miRNA-22-3p had significantly different expression in patients with precancerous lesions or gastric adenocarcinoma. The areas under the curve of incomplete IM versus healthy control, low-grade/high-grade dysplasia, early gastric cancer, and GED were 0.8080, 0.8040, 0.8494, and 0.8095, respectively (all P values < 0.05). CONCLUSIONS: Circulating miRNA-22-3p could be a potential biomarker for gastric precancerous dysplasia and early cancer detection.
BACKGROUND:Gastric cancer has a poor outcome and identifying useful biomarkers from peripheral blood or tissue could allow its early detection, or potentially precancerous changes, thus improving the curative rates. MicroRNAs (miRNAs) have been shown to offer great potential in cancer diagnosis and prediction. AIM: Here, we investigated the role of plasma miRNAs in the natural course of gastric cancer, from intestinal metaplasia to early cancer. The findings were used to understand whether patients at a high risk of malignancy could be given appropriate interventions in the early disease process, such as using endoscopic submucosal dissection to treat gastric dysplasia or early gastric cancer. METHODS:Participants were divided into healthy control, intestinal metaplasia (IM), and dysplasia/early cancer (pT1a/b) groups. Microarray was used to select potential markers in tissue. RESULTS: Quantitative real-time polymerase chain reaction data showed circulating miRNA-22-3p had significantly different expression in patients with precancerous lesions or gastric adenocarcinoma. The areas under the curve of incomplete IM versus healthy control, low-grade/high-grade dysplasia, early gastric cancer, and GED were 0.8080, 0.8040, 0.8494, and 0.8095, respectively (all P values < 0.05). CONCLUSIONS: Circulating miRNA-22-3p could be a potential biomarker for gastric precancerous dysplasia and early cancer detection.
Authors: Carlos A González; Maria Luisa Pardo; Juan Maria Ruiz Liso; Pablo Alonso; Catalina Bonet; Raul M Garcia; Núria Sala; Gabriel Capella; José Miguel Sanz-Anquela Journal: Int J Cancer Date: 2010-12-01 Impact factor: 7.396
Authors: M Tsujiura; D Ichikawa; S Komatsu; A Shiozaki; H Takeshita; T Kosuga; H Konishi; R Morimura; K Deguchi; H Fujiwara; K Okamoto; E Otsuji Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640
Authors: Martha L Slattery; Jennifer S Herrick; Daniel F Pellatt; John R Stevens; Lila E Mullany; Erica Wolff; Michael D Hoffman; Wade S Samowitz; Roger K Wolff Journal: Carcinogenesis Date: 2016-01-06 Impact factor: 4.944